Suraksha Diagnostics is preparing to launch its IPO, targeting the growing healthcare demand in Eastern India, specifically in West Bengal. The company specializes in diagnostic services, with a strong focus on radiology and pathology, positioning itself to serve an underserved market.

The IPO includes an Offer for Sale (OFS) that allows private equity investors to partially exit their investments. Suraksha Diagnostics has a significant business-to-consumer (B2C) mix, which improves its cash conversion cycle, making it an attractive investment opportunity. Valuation metrics suggest that Suraksha Diagnostics is priced at a discount compared to its close peers, potentially appealing to investors seeking value in the healthcare sector.

The IPO comes at a time when localized players in the diagnostic space, such as Vijaya Diagnostic and KIMS, have gained traction, highlighting the increasing demand for healthcare services in the region.